Equity Profile

CNTA

Centessa Pharmaceuticals plc

Health CareBiotechnology$6.3B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Centessa Pharmaceuticals plc is a biotechnology company focused on developing innovative therapies for various diseases. Operating in the health care sector, it aims to address unmet medical needs through its unique drug development approach.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of -$0.52, missing expectations by a significant margin. The stock reacted with a slight decline of 0.08% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to improving operational efficiency.
Plans to provide updates on regulatory submissions.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's innovative pipeline but wary due to recent earnings misses.

Bull Case

If Centessa can demonstrate progress in its clinical trials and improve its EPS, it could lead to a strong positive reaction from investors.

Bear Case

Continued losses and lack of clear progress in drug development could further erode investor confidence and lead to a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can Centessa report regarding its clinical trials?

Progress in clinical trials is crucial for validating the company's drug pipeline and can significantly influence stock performance.

How does Centessa plan to address its recent earnings misses and improve profitability?

Investors will be keen to understand the company's strategy to enhance financial performance and restore confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa's drug candidates to show significant clinical progress, which could lead to a positive surprise.

Supporting Evidence

The options market is pricing in a 17.42% move, indicating expectations for volatility that may not align with the actual outcomes.

Centessa's recent advancements in clinical trials have not been fully reflected in analyst expectations.

The company's unique approach to drug development could yield better-than-expected results.

Key Risk

If clinical trial results show unexpected positive outcomes, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around the company's ability to improve its financial metrics while advancing its drug development pipeline.

Bull Confirmed If

Demonstrating a path to profitability with a reduced EPS loss of less than -$0.40.

Bear Confirmed If

Further widening of EPS losses beyond -$0.52 would confirm ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations and raises guidance, history suggests a potential stock increase of around 0.04%, confirming bullish sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess.

Miss

If the company misses expectations again, history suggests a potential decline of around 8.63%, indicating ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Management's strategy for addressing recent financial performance issues.
3Any commentary on partnerships or collaborations that could enhance growth.
4Insights into the competitive landscape and how Centessa plans to differentiate itself.
5Future guidance on expected timelines for product launches.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of -$0.52, missing expectations by a significant margin. The stock reacted with a slight decline of 0.08% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to improving operational efficiency.
Plans to provide updates on regulatory submissions.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's innovative pipeline but wary due to recent earnings misses.

Bull Case

If Centessa can demonstrate progress in its clinical trials and improve its EPS, it could lead to a strong positive reaction from investors.

Bear Case

Continued losses and lack of clear progress in drug development could further erode investor confidence and lead to a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can Centessa report regarding its clinical trials?

Progress in clinical trials is crucial for validating the company's drug pipeline and can significantly influence stock performance.

How does Centessa plan to address its recent earnings misses and improve profitability?

Investors will be keen to understand the company's strategy to enhance financial performance and restore confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa's drug candidates to show significant clinical progress, which could lead to a positive surprise.

Supporting Evidence

The options market is pricing in a 17.42% move, indicating expectations for volatility that may not align with the actual outcomes.

Centessa's recent advancements in clinical trials have not been fully reflected in analyst expectations.

The company's unique approach to drug development could yield better-than-expected results.

Key Risk

If clinical trial results show unexpected positive outcomes, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around the company's ability to improve its financial metrics while advancing its drug development pipeline.

Bull Confirmed If

Demonstrating a path to profitability with a reduced EPS loss of less than -$0.40.

Bear Confirmed If

Further widening of EPS losses beyond -$0.52 would confirm ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations and raises guidance, history suggests a potential stock increase of around 0.04%, confirming bullish sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess.

Miss

If the company misses expectations again, history suggests a potential decline of around 8.63%, indicating ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Management's strategy for addressing recent financial performance issues.
3Any commentary on partnerships or collaborations that could enhance growth.
4Insights into the competitive landscape and how Centessa plans to differentiate itself.
5Future guidance on expected timelines for product launches.